PUR logo

Pure Biologics S.A. Stock Price

WSE:PUR Community·zł21.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

PUR Share Price Performance

zł5.37
-13.53 (-71.59%)
zł5.37
-13.53 (-71.59%)
Price zł5.37

PUR Community Narratives

There are no narratives available yet.

Snowflake Analysis

Medium-low risk with weak fundamentals.

6 Risks
0 Rewards

Pure Biologics S.A. Key Details

zł0

Revenue

zł41.0k

Cost of Revenue

-zł41.0k

Gross Profit

zł13.0m

Other Expenses

-zł13.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-3.19
0%
0%
-80.4%
View Full Analysis

About PUR

Founded
2010
Employees
6
CEO
Filip Jelen
WebsiteView website
purebiologics.com

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis; and provides contract research for pharmaceutical and biotechnology companies. Pure Biologics S.A. was incorporated in 2010 and is headquartered in Wroclaw, Poland.

Recent PUR News & Updates

Recent updates

No updates